2 weeks Ago By Defense World Staff
American Century Companies Inc. lowered its stake in Genmab A/S (NASDAQ:GMAB – Free Report) by 19.3% in the 4th quarter, according to its most recent filing with the SEC.
The fund owned 320,575 shares of the company’s stock after selling 76,505 shares during the period. American Century Companies Inc.’s holdings in Genmab A/S were worth $6,690,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd.
increased its holdings in Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co.
Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after buying an additional 827 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Genmab A/S by 295.
3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its holdings in shares of Genmab A/S by 105.
4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 96.
6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares during the last quarter. Finally, Grandfield & Dodd LLC raised its position in shares of Genmab A/S by 4.
2% during the 4th quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company’s stock valued at $704,000 after acquiring an additional 1,370 shares in the last quarter. Institutional investors and hedge funds own 7.
07% of the company’s stock. Genmab A/S Stock PerformanceNASDAQ:GMAB opened at $19.24 on Friday.
The stock has a market cap of $12.73 billion, a price-to-earnings ratio of 11.06, a PEG ratio of 2.
65 and a beta of 0.98. Genmab A/S has a 1 year low of $18.
48 and a 1 year high of $30.50. The business has a fifty day moving average of $20.
72 and a 200-day moving average of $21.70. Genmab A/S (NASDAQ:GMAB – Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th.
The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.
29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.
78%. On average, equities research analysts predict that Genmab A/S will post 1.45 EPS for the current year.
Wall Street Analyst Weigh InA number of research firms have commented on GMAB. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd.
Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, February 13th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 11th.
Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company.
According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $41.33.
Get Our Latest Report on GMABGenmab A/S Company Profile (Free Report)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.Read MoreFive stocks we like better than Genmab A/SWhat Are Trending Stocks? Trending Stocks ExplainedShares of RH Down Nearly 40%: Where Investors Can Turn To NowThere Are Different Types of Stock To Invest InTariffs, Spin-Out, and R2 Updates Are Positive Signs for RivianHow to Use the MarketBeat Stock Screener Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?.
